Primo-indication
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens.
Intervention Type
Pharmaceutical
Solid/Hematological
Solid
Cancer Type
Breast
Therapy Types
Targeted Therapy
Regulatory
FDA
N/A
Regulatory Pathway: n/a
EMA
11.02.2021
Regulatory Pathway: standard approval
Availability in other countries
N/A
Focus Area
Cancer
ASMR
III
Medical Need
Partially met
SMR
IMPORTANT
Orphan Status
No